ABT 110

Drug Profile

ABT 110

Alternative Names: ABT-110; HU αD11; Hu-alpha-D11; HuAlphaD11; PG-110

Latest Information Update: 05 Feb 2013

Price : $50

At a glance

  • Originator Lay Line Genomics
  • Developer AbbVie
  • Class Analgesics; Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Back pain; Pain

Most Recent Events

  • 26 Jan 2013 Discontinued - Phase-II for Pain in Argentina (IV)
  • 26 Jan 2013 Discontinued - Phase-II for Pain in Australia (IV)
  • 26 Jan 2013 Discontinued - Phase-II for Pain in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top